Enhanced productivity and functionality of Modified Ribosomally Produced Peptides (M-RIPPs)

核糖体产生的多肽（RIPPs）被广泛认为是最有前途的一类化合物之一，具有治疗多种疾病的潜力，包括感染、癌症和炎症。制药行业对它们非常感兴趣，但生产/修改它们的成本极高——即使是以毫克为单位。通过利用组合合成生物学的尖端技术，该项目旨在实现世界第一；也就是说，生产定制的修改RIPPs （M-RIPPs）的文库，其数量足以进行药物发现筛选。该项目结合了活跃在该领域的两个英国顶级学术团体的RIPP生物合成中涉及的自然过程的基础知识，以及英国一家领先的IB公司在工业生物合成方面的应用专业知识。它将为m - ripp的生产提供一个多功能而强大的技术平台，该平台将在项目开始后18个月左右转移到一个分拆公司。

Ribosomally Produced Peptides (RIPPs) are widely recognised as one of the most promising classes of compounds with the potential to treat many diseases including infection, cancer & inflammation. They are of great interest to the pharma industry, but are extremely costly to produce/modify - even in milligram amounts. Through the utilisation of cutting-edge techniques in combinatorial synthetic biology, this project sets out to achieve a world first; namely, to produce bespoke libraries of Modified RIPPs (M-RIPPs) in sufficient quantities to permit drug discovery screening. The project combines the fundamental knowledge of the natural processes involved in RIPP biosynthesis of the two premier UK academic groups active in the field with the applied expertise in industrial biosynthesis of a leading UK IB company. It will deliver a versatile yet robust technology platform for the production of M-RIPPs that will be transferred to a spinoff company to be formed around 18 months after project start.